Mutational Analysis of Driver and Non-driver Mutations of Philadelphia Chromosome-negative Myeloproliferative Neoplasms; Diagnosis and Recent Advances in Treatment

World Journal of Cancer and Oncology Research | Vol 3, Issue 1

Figure 6

Inhibitory<b> </b>effect of Ruxolitinib on MPN progression; blue arrows indicate the normal JAK/STAT pathway and red arrows indicate the overactivation of the JAK/STAT pathway due to driver mutations.

Figure 6. Inhibitory effect of Ruxolitinib on MPN progression; blue arrows indicate the normal JAK/STAT pathway and red arrows indicate the overactivation of the JAK/STAT pathway due to driver mutations.